• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference

    11/5/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email

    Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY.

    Presentation Information

    A live and recorded webcast of the presentation will be available at:

    https://event.webcasts.com/starthere.jsp?ei=1742138&tp_key=f2a06e9abc

    About Adagio Medical Holdings, Inc.

    Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251105837821/en/

    Debbie Kaster

    Chief Financial Officer and Chief Business Officer

    [email protected]

    Get the next $ADGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    12/2/2025$4.00Buy
    Lake Street
    More analyst ratings

    $ADGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

    Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys

    12/22/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

    Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl

    12/11/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    SEC Filings

    View All

    SEC Form 424B3 filed by Adagio Medical Holdings Inc

    424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    12/16/25 4:41:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Adagio Medical Holdings Inc

    424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    12/16/25 4:40:46 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Holdings Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    12/16/25 4:15:32 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Salmon Sean

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/11/25 9:51:26 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Adagio Medical Holdings with a new price target

    Lake Street initiated coverage of Adagio Medical Holdings with a rating of Buy and set a new price target of $4.00

    12/2/25 8:38:52 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    View All

    Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

    Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys

    12/22/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

    Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl

    12/11/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/24 4:30:17 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    8/12/24 4:22:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care